Azafaros announces completion of 12-week Phase 2 RAINBOW
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients Major milestone reached ...
Read moreAzafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients Major milestone reached ...
Read moreNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, ...
Read moreNot for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC, Feb. 23, 2024 ...
Read moreSafety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of ...
Read moreVenlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details ...
Read moreMIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a ...
Read moreThe 17,000sqm unprecedented art project will offer a multi-sensory exploration of experiential artworks created by art collective teamLab ABU DHABI, ...
Read moreNAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy ...
Read moreIRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (Nasdaq: CAMP), a connected intelligence company helping people and organizations improve ...
Read moreCLEVELAND, Dec. 12, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. today announced the final patient was enrolled in the RESET ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.